Association between Neck Circumference and the Occurrence of Cardiovascular Events in Type 2 Diabetes: Beijing Community Diabetes Study 20 (BCDS-20)

Table 2

Baseline clinical characteristics in the cardiovascular group and the noncardiovascular group in men.

	Total ()	Non-CVD group ()	CVD group ()	t value	value
Age (years)	67.22 ± 12.11	66.75 ± 12.27	72.02 ± 8.95	−5.55	<0.001
BMI (kg/m^2)	25.30 ± 3.51	25.25 ± 3.47	25.81 ± 3.88	−1.57	0.118
Diabetic duration (years)	10.1 (6.1, 15.3)	10.0 (6.0, 15.2)	12.8 (7.1, 16.8)	2.54 (Z)	0.011
Smoking (n, %)	386 (32.33)	358 (32.87)	28 (26.67)	1.69 (x2)	0.194
WC (cm)	91.10 ± 8.81	90.90 ± 8.78	93.20 ± 8.90	−2.56	0.010
NC (cm)	38.20 ± 3.80	38.22 ± 3.73	38.02 ± 4.49	0.43	0.665
SBP (mmHg)	129.53 ± 14.50	129.26 ± 14.37	132.36 ± 15.59	−2.08	0.037
DBP (mmHg)	78.54 ± 9.06	78.54 ± 9.03	78.52 ± 9.35	0.02	0.984
FPG (mmol/L)	7.90 ± 2.69	7.89 ± 2.73	7.99 ± 2.27	−0.41	0.681
HbA1c (%)	7.39 ± 1.67	7.38 ± 1.69	7.57 ± 1.46	−1.10	0.270
TG (mmol/L)	1.80 ± 1.48	1.80 ± 1.51	1.74 ± 1.23	0.50	0.621
TC (mmol/L)	5.03 ± 1.20	5.02 ± 1.20	5.13 ± 1.18	−0.93	0.352
HDL (mmol/L)	1.24 ± 0.41	1.24 ± 0.42	1.19 ± 0.35	1.53	0.128
LDL (mmol/L)	2.94 ± 0.88	2.93 ± 0.89	3.00 ± 0.75	−0.82	0.416
Antihypertension medication (n, %)	669 (56.03)	597 (54.82)	72 (68.57)	7.35 (x2)	0.007
Antiglycemic medication (n, %)	1073 (89.87)	971 (89.16)	102 (97.14)	6.69 (x2)	0.010
Statin (n, %)	730 (61.14)	661 (60.7)	69 (65.71)	1.01 (x2)	0.314

Rank sum test was used, expressed as median (range). Chi-square was used. CVD, cardiovascular disease; BMI, body mass index; WC, waist circumference; NC, neck circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.